ViroPharma (VPHM +2.6%) gains after releasing positive results from trials of its Cinryze, a...

|By:, SA News Editor

ViroPharma (VPHM +2.6%) gains after releasing positive results from trials of its Cinryze, a therapy approved for routine prevention of angioedema attacks in patients with hereditary forms of the disease. The study showed a 54.7% decrease in attack rate for those patients treated with Cinryze over the period, which is similar to the reduction in attack rate (52%) from the overall study population.